OcugenOCGN
Recorded

Ocugen Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration32 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

All right. Great. Excellent. Good morning, everyone, and welcome to the Ocugen presentation. Happy to have Shankar Musunuri with us today, CEO of Ocugen. As you know, Ocugen is developing gene therapies for various diseases causing blindness that are gene agnostic. Maybe to give you a little bit of a better description than I did, Shankar, you can come up and give your presentation.

Shankar MusunuriCEO

Thank you. Thank you for having me here today. Good morning, everyone. Morning. Forward-looking statement.

Shankar MusunuriCEO

We are leaders in ophthalmology gene therapy. If you take vision loss or blindness diseases today, the major ones, inherited diseases, as well as diseases such as dry age-related macular degeneration, we have products targeting all those diseases. I mean, covering the majority of the vision loss diseases today. They are all in late-stage phase III clinical trials. How are we able to target large populations compared to gene therapy for everybody is like, you know, precision medicine. You got a genetic mutation, you target, sometimes it is 50 patients, 200 or 2,000. We have modifier gene therapy platform, which are like master regulators. When you have any genetic defect starts from birth. The toxic protein you are producing that has impact on the entire gene network of functioning genes. That is always there. By giving a traditional gene therapy, it is good depending on when you give it early on.

Shankar MusunuriCEO

What we found out, the key functioning genes responsible in the genetic network, genes don't work in isolation, they work as a network, such as cell development, inflammation, metabolism to cell survival. These key functioning genes are depressed, and there is a link that links up to a nuclear hormone receptor gene master regulator, and that is depressed. When you upregulate, the whole system comes back to life and resets the cellular homeostasis, restores the function. That is very important. Why? Retinal cells are non-dividing cells. If I can do something to reset them, potentially they should survive rest of your life. We have four groundbreaking publications in Nature. Today, we see the results in humans.

Shankar MusunuriCEO

I cannot sit here and promise every patient is going to stop their disease progression and reverse it. You do not need to do that to get drugs approved. If you slow down the disease progression, you will get the drug approved. In some of these cases, we are getting long-term data. I can see these patients, some of them, they stopped disease progression. Some of the patient, it is reversing it. Also, complex diseases such as macular degeneration, they got many pathways. There are a couple of products for GA today, dry age-related macular degeneration. They target one of those pathways. If you target just one pathway, the results may not be optimum. Our another master regulator gene modulates all those pathways, also resets the cellular homeostasis. That means creating a healthy environment for retinal cells as well as RPE cells to survive.

Shankar MusunuriCEO

The programs in phase III clinical trials today, the top one is OCU400, targeting retinitis pigmentosa. We have a gene-agnostic indication. It targets RP can be caused by mutations in over 100 genes. This one targets all the population, very broad indication. Also, pediatric to adult, early to advanced stage. Topline results are expected in first quarter next year. Today, I will go a little more into that, what it means, what these results mean to us. The second program, OCU410ST, targeting Stargardt disease, is going through phase II/III parallel clinical trial. Topline results are expected in second quarter of next year, and followed by the BLA and market authorization applications. The last one, OCU410, is a large program. Our team, I am very proud of them, they have done a phenomenal job.

Shankar MusunuriCEO

Within four months, after phase II data came out, they had a meeting with FDA, end of phase II. Followed by that, we got a Regenerative Medicine Advanced Therapy designation, which is rare, given to a large disease burden. Typically, it is given to cell and gene therapies, which are orphan in nature. Because of significant unmet medical need, promising data we generated in phase II, even though there are a couple of products in the market for GA, we still got our RMAT. FDA still believes there is a significant unmet medical need. This is going to be a game changer for this patient population. We are recruiting patients right now. This clinical trial is going on in U.S., Canada, and EU. It is a global trial of 240 patients. We are hopeful to complete recruitment next year. It is a one-year duration.

Shankar MusunuriCEO

All our clinical trials are one year, because we are able to show effect in patients in one year. Since all these diseases are significant unmet medical needs, regulatory agencies are working with us. Anybody in this space, they all do two years clinical trials. With that, what I would like to do, walk you through OCU400. The topline results are expected by first quarter of next year, in 2027. I wanted to just to recap, what is the primary endpoint? How did we drive into that? And what the results mean. In phase I/II, we had a gene-agnostic approach. We had multiple mutations, including rhodopsin, which is a significantly autosomal dominant, which is very difficult with the traditional gene therapies. It is 10%-12% of the entire 100,000 RP population. We had promising results. The safety looks good.

Shankar MusunuriCEO

We don't have any SAEs related to our gene therapy. The majority of the patients, about 89% showed stabilization or improvement with one of the critical functional measures. We also released this year three data, long-term durability, and it looks good. Patients are continuing to do well. That's important. What is the primary endpoint in phase III clinical trial? It's based on mobility test. This test is similar to one of the products, LUXTURNA, first product got approval. What it means is, most of the RP patients lose their peripheral vision first, then they have night vision, then they have central vision left. Some part of their life, they'll become legally blind.

Shankar MusunuriCEO

What it test measures is, if very analogous to, if you go to a restaurant, today, I need somebody's help to take me in a dull light to go sit in my chair. Here, after the treatment with the gene therapy, if I can go walk through in a dull light, and navigate and sit in my chair, that means I have improved. That's improving quality of life. The test is similar to that. It goes through from bright light to dull light, bright light, sunlight to dull moonlight, you can think of. If I'm improving couple of levels after the treatment, after one year, that means I'm making significant progress in functional vision. In phase I/II, we used mobility test. That's orange bars show that. There, we compared ITT population which meets phase III clinical trial.

Shankar MusunuriCEO

Only certain percentage of the phase I meets phase III population because there are some restrictions, because there is also ceiling effect. In phase I/II, for example, the course ended at 0.1 lux levels. That means if I'm at 0.1, even you're improving, I cannot measure you. FDA worked with us, thanks to them. They said, "Why are you stopping at that? Go to 0.24." That way, you can still take patients at 0.1, you can show the improvement. Also, we expanded on the other end to 500. Because of that, the levels increased. You can see the course. FDA actually asked us to change that. You don't need to have logarithmic differences in some levels. You can actually even them out, which makes it easier actually to pass in phase III.

Shankar MusunuriCEO

If you take that phase III course, we had a 71% passing two levels. That's a metric we had to meet in phase III. We used the data, we moved into phase III. It's 140-patient trial, largest genetic medicine trial in the world to date. All the gene therapies approved by FDA, many of them had about 50 patients or less. We have recruited about 30 genetic mutations in this clinical trial. Anything which has a 1% or 2% of RP and above, major ones, they're in the trial. Having that 140 patients, a pooled analysis gives a very good power, 99%. So we pulled a buffer at 70%, 71% in phase I/II.

Shankar MusunuriCEO

We said, "Okay, we'll build a buffer, 50% responder rate." Even though you saw zero untreated eyes reaching two levels, we said, "Okay, 10%, a risk mitigation." That gives us 99% power. In reality, my team thinks, we validated the course for phase III. It's sensitive and specific compared to what others have used in the past. My team says it's very robust. KOLs believe it's a very robust course. Even improving one level is clinically meaningful. My team believes reaching two levels for untreated arm, two levels is almost very difficult. That means if they don't reach, just like in phase I/II, if they have 0 or 1%, all we need is 20% responder rate to hit the endpoint. This is a very nicely designed trial, and we are very excited about looking forward to the phase III data.

Shankar MusunuriCEO

This is geared, the team is working hard. The data should come on time by the end of first quarter, and we're going to immediately meet with FDA for a pre-BLA meeting and keep moving with our BLA. The goal is to file the BLA by second quarter, and then that will give us accelerated priority review because we have orphan drug designation, RMAT designation. That should put us in fourth quarter of 2027 of PDUFA date potentially, and get approval and launch the product. Right after FDA BLA filing, we'll also file MAA in Europe. We're also working with PMDA in Japan. All those filings will go, and the international filings will follow. Now, I'll spend a couple of minutes before we go into Q&A. I want to focus on the commercial potential. The three products we're working on, we're not even surfacing beyond U.S. and E.U.

Shankar MusunuriCEO

We just take these two markets, and RP has 300,000 patients. The pricing based on pharmacoeconomics, $1 million-$2 million is very reasonable. If you take a midpoint of $1.5 million, 300,000 fraction of the patients, that's a huge opportunity commercially, multi-billion dollars per year. Same thing with Stargardt. When you go to GA, that's a huge opportunity. I mean, 2 million patients in U.S. and E.U. If we can treat 100,000 patients a year, if you pick a midpoint or even the lowest point of $300,000 a patient, it's a huge opportunity for Ocugen and our shareholders. All these products, again, we are not targeting 50 patients or even 2,000 patients. We're going after hundreds of thousands to millions with a potential one-time treatment. That means we have a very significant commercial opportunity. Now, I'm going to show you what it means. Take these three diseases. Irrespective of people are working with other modalities, it doesn't matter.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day